Collaborative and Other Relationships - Profit Sharing (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
RITUXAN
Collaborative arrangements and non-collaborative arrangement transactions
Percentage of co promotion operating profits first fifty million	30.00%
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date	37.50%
GAZYVA
Collaborative arrangements and non-collaborative arrangement transactions
Percentage of co promotion operating profits first fifty million	35.00%
Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment	$ 50.0
Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one	150.0
Limit of gross sale of GAZYVA to be achieved in any 12 months under option one	150.0
Sales trigger gross sales threshold	$ 500.0
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date	37.50%	37.50%	37.50%
New Anti Cd20
Collaborative arrangements and non-collaborative arrangement transactions
Future percentage of co-promotion operating profits	37.50%	37.50%	37.50%
New Anti Cd20 | Minimum
Collaborative arrangements and non-collaborative arrangement transactions
Future percentage of co-promotion operating profits	30.00%
New Anti Cd20 | Maximum
Collaborative arrangements and non-collaborative arrangement transactions
Future percentage of co-promotion operating profits	37.50%
Mosunetuzumab | Minimum
Collaborative arrangements and non-collaborative arrangement transactions
Future percentage of co-promotion operating profits	30.00%
Mosunetuzumab | Maximum
Collaborative arrangements and non-collaborative arrangement transactions
Future percentage of co-promotion operating profits	37.50%